CliffBio
biologic

Lynozyfic

linvoseltamab-gcpt

Loss of exclusivityJuly 2037projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameLynozyfic
Active ingredientlinvoseltamab-gcpt
Strength200MG/10ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2025
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lynozyfic patent cliff — loss of exclusivity July 2037 | CliffBio